LIGHTBEAM-U01 Substudy 01E belzutifan in solid tumors

Phase 2, open-label, single-arm trial of belzutifan in pheochromocytoma, Paraganglioma (PGL), gastrointestinal stromal tumor (GIST) and 2 more, sponsored by Merck & Co. Primary endpoints: Number of participants who experience one or more adverse events and Number of participants who discontinue study intervention due to an adverse event. Planned start Oct 2026; status: authorised.